These biomarkers improved prognostic discrimination and patient re-classification for CV death or HF at 1 year ( all categorical NRI > 10 % , p < 0.001 ) , and maintained independent association with composite CV death or HF when concurrently assessed in a model with clinical indicators plus BNP , cTnI , ST2 , PAPP-A , and MPO ( each p0 .01 ) [ corrected ] .